MedImmune venture capital arm leads financing of cancer drug developer G1

19:20 EDT 16 Oct 2013 | SCRIP

Chapel Hill, North Carolina-based G1 is studying a treatment for myelosuppression, a side effect of chemotherapy that limits production of blood cells and platelets. The company said it plans to file an investigational new drug application with the U...

Original Article: MedImmune venture capital arm leads financing of cancer drug developer G1

NEXT ARTICLE

More From BioPortfolio on "MedImmune venture capital arm leads financing of cancer drug developer G1"

Search BioPortfolio:
Advertisement

Relevant Topics

Blood
Latest News Clinical Trials Research Drugs Reports Corporate
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Pharmacy
Latest News Clinical Trials Research Drugs Reports Corporate
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Advertisement

Searches Linking to this Story